Harith Rajagopalan, Fractyl Health CEO
Fractyl pitches potential of GLP-1 gene therapy, but pushes clinical trials back to 2025
A small biotech company is developing a one-time gene therapy that could turn the pancreas into its own GLP-1 drug factory and eliminate the need …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
